139 related articles for article (PubMed ID: 9226653)
1. Anti-OspA antibody reduces reservoir competence of mice for Borrelia burgdorferi, the agent of Lyme disease.
Brunet LR; Katavolos P; Spielman A; Telford SR
Med Vet Entomol; 1997 Apr; 11(2):198-200. PubMed ID: 9226653
[No Abstract] [Full Text] [Related]
2. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine.
Wallich R; Kramer MD; Simon MM
Infection; 1996; 24(5):396-7. PubMed ID: 8923055
[No Abstract] [Full Text] [Related]
3. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
[TBL] [Abstract][Full Text] [Related]
4. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.
Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E
Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431
[TBL] [Abstract][Full Text] [Related]
5. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
Luke CJ; Carner K; Liang X; Barbour AG
J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
[TBL] [Abstract][Full Text] [Related]
6. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
7. Borrelia burgdorferi antigens that are targeted by antibody-dependent, complement-mediated killing in the rhesus monkey.
Aydintug MK; Gu Y; Philipp MT
Infect Immun; 1994 Nov; 62(11):4929-37. PubMed ID: 7927774
[TBL] [Abstract][Full Text] [Related]
8. Detection of Lyme disease after OspA vaccine.
Schutzer SE; Luan J; Coyle PK
N Engl J Med; 1997 Sep; 337(11):794-5. PubMed ID: 9289653
[No Abstract] [Full Text] [Related]
9. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
10. Immunization against Lyme disease--an important first step.
Steigbigel RT; Benach JL
N Engl J Med; 1998 Jul; 339(4):263-4. PubMed ID: 9673306
[No Abstract] [Full Text] [Related]
11. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies.
Kurtenbach K; Dizij A; Voet P; Hauser P; Simon MM
Vaccine; 1997 Oct; 15(15):1670-4. PubMed ID: 9364698
[TBL] [Abstract][Full Text] [Related]
12. Borrelia burgdorferi outer surface protein A vaccine: importance, role, and value.
Sigal LH
J Pediatr; 1999 Nov; 135(5):539-41. PubMed ID: 10547238
[No Abstract] [Full Text] [Related]
13. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
14. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
15. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.
Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC
Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292
[TBL] [Abstract][Full Text] [Related]
16. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.
Luke CJ; Huebner RC; Kasmiersky V; Barbour AG
Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476
[TBL] [Abstract][Full Text] [Related]
17. Epitopes on surface antigens other than OspA can elicit a bactericidal effect against Lyme disease borrelias.
Shoberg RJ; Thomas DD
J Infect Dis; 1995 Jan; 171(1):253-4. PubMed ID: 7528252
[No Abstract] [Full Text] [Related]
18. OspA immunization decreases transmission of Borrelia burgdorferi spirochetes from infected Peromyscus leucopus mice to larval Ixodes scapularis ticks.
Tsao J; Barbour AG; Luke CJ; Fikrig E; Fish D
Vector Borne Zoonotic Dis; 2001; 1(1):65-74. PubMed ID: 12653137
[TBL] [Abstract][Full Text] [Related]
19. Effects of OspA vaccination on Lyme disease serologic testing.
Aguero-Rosenfeld ME; Roberge J; Carbonaro CA; Nowakowski J; Nadelman RB; Wormser GP
J Clin Microbiol; 1999 Nov; 37(11):3718-21. PubMed ID: 10523583
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
Scheckelhoff MR; Telford SR; Hu LT
Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
